Large-scale trials have demonstrated that SGLT2 inhibitors reduce the risk of gout flares by 30% to 50%, translating into meaningful improvements in patient quality of life, particularly among those with comorbid hyperuricemia [122]. Here, SLC5A2 is linked to hyperuricemia.